Shares of Tiziana Life Sciences PLC (LON: TILS) today surged 14.9% higher after the company announced that human trials of its Foralumab drug on COVID-19 patients would start soon.
The company is moving straight into human trials because it had collected and analysed safety data for the drug, which is applied as a nasal spray in a phase 1 trial conducted last year.
Foralumab is a fully human anti-CD3 monoclonal antibody, which acts by suppressing an overreaction by the human immune system also known as a cytokine storm in people that are worst-affected by the coronavirus.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Tiziana yesterday announced plans to spin-off its diagnostics business in order to focus on its clinical work and its now clear why the company chose to go in that direction.
The human trials will start in a few weeks with the first tests being conducted in Brazil as early as next month.
Dr Howard Weiner, the chairman of Tiziana’s scientific advisory board, said: “Nasal administration of Foralumab to modulate the human immune system is a potentially transformative approach for treating patients with a variety of human diseases with the dysregulated immune system.”
Dr Howard is a globally recognised neurologist.
Tiziana share price
Tiziana shares were up 14.9% to trade at 169p at the time of writing having closed Wednesday’s session trading at 147p.
People who read this also read:
